TZF on the CPhI

On 04th-07th of November, TZF will take a part in the world’s largest pharmaceutical event – CPHI, which year by year have hosted more than 45 000 industry experts. Our team of experts will be delighted to provide you insights about the company and possible cooperation area, such as FDF and API portfolio availability for out-licensing & distribution or Contract Manufacturing. Hall 9.1, zone FDF, stand: 91H80, Frankfurt Messe.

  • Core of our production:
    • Prescritpion drugs (Anfi-infection for systematic use, Alimentary

Polfa Tarchomin on the CPhI

On 09th-11th of October, Polfa Tarchomin took a part in the world’s largest pharmaceutical event – CPHI, which have hosted more than 45 000 industry experts. Polfa Tarchomin was among 2500 exhibitors with its own stand. During the event we have hosted dozens  of the pharmaceutical companies representatives. Attending CPhI Worldwide is an effective way to establish new business relationships and stay updated on the latest industry trends. The exhibition showcases cover the whole spectrum of pharmaceutical manufacturing…

Tonasen – a new product in our offer, 26.09.2013

At the end of August, Polfa Tarchomin started selling its new product – a non-prescription drug. Tonasen, a synthetic counterpart to the natural hormone – melatonin, is a drug used in case of sleeping disorders. Tonasen is used as an excipient in sleeping disorders related to, for example, changing time zones or working in shifts. Disruptions of a person’s biological rhythm are one of the reasons for melatonin deficiency. In addition, the product facilitates adjustment of sleeping patterns and wakefulness of blind patients.…

New PolhuminPen – a modern insulin pen, 10.06.2015

Polhumin Pen is an intuitive insulin pen, which was designed in Switzerland. It allows for injection of up to 60 units of insulin at one time, which is important in therapy of patients with high insulin resistance. Another benefit of the new PoluminPen is the possibility of adjusting the dose by units. It is of special significance in case of intensive insulin therapy, during which the patient adjusts the dose of insulin to his/her body’s current needs indicated by the blood sugar level. In addition, the patient is able to correct…

Project co-financed with the participation of the domestic founds and EU Funds

Public Information Bulletin